Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy

World Journal of Surgical Oncology

Nengwei Zhang²  Zhipeng Sun¹ 

[1] Oncology Surgery Department, Capital Medical Cancer Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;Beijing Shijitan Hospital, Capital Medical University, Room 334, Administrative Building, Beijing 100038, China

关键词: CA125;    CA72-4;    CA19-9;    CEA;    Neoadjuvant chemotherapy;    Gastric cancer;   

Others  :  1146711
DOI  :  10.1186/1477-7819-12-397

 received in 2014-10-05, accepted in 2014-12-05,  发布年份 2014

【 摘 要 】

Background

In the clinical practice of neoadjuvant chemotherapy, response markers are very important. We aimed o investigate whether tumor markers CEA(carcino-embryonic antigen), CA19-9(carbohydrate antigen 19–9), CA72-4(carbohydrate antigen 72–4), and CA125(carbohydrate antigen 125) can be used to evaluate the response to neoadjuvant chemotherapy, and to evaluate the diagnosis and prognosis value of four tumor markers in the patients of gastric cancer.

Methods

A retrospective review was performed of 184 gastric cancer patients who underwent a 5-Fu, leucovorin, and oxaliplatin (FOLFOX) neoadjuvant chemotherapy regimen, followed by surgical treatment. Blood samples for CEA, CA19-9, CA72-4, and CA125 levels were taken from patients upon admission to the hospital and after neoadjuvant chemotherapy. Statistical analysis was performed to identify the clinical value of these tumor markers in predicting the survival and the response to neoadjuvant chemotherapy.

Results

Median overall survival times of pretreatment CA19-9-positive and CA72-4-positive patients (14.0 +/−2.8 months and 14.8 +/−4.0 months, respectively) were significantly less than negative patients (32.5 +/−8.9 months and 34.0 +/−10.1 months, respectively) (P = 0.000 and P = 0.002, respectively). Pretreatment status of CA19-9 and CA72-4 were independent prognostic factors in gastric cancer patients (P = 0.029 and P = 0.008, respectively). Pretreatment CEA >50 ng/ml had a positive prediction value for clinical disease progression after neoadjuvant chemotherapy according to the ROC curve (AUC: 0.694, 95% CI: 0.517 to 0.871, P = 0.017). The decrease of tumor markers CEA, CA72-4, and CA125 was significant after neoadjuvant chemotherapy (P = 0.030, P = 0.010, and P = 0.009, respectively), especially in patients with disease control (including complete, partial clinical response, and stable disease) (P = 0.012, P = 0.020, and P = 0.025, respectively). A decrease in CA72-4 by more than 70% had a positive prediction value for pathologic response to neoadjuvant chemotherapy according to the ROC curve (AUC: 0.764, 95% CI: 0.584 to 0.945, P = 0.020).

Conclusions

Our results suggest that high preoperative serum levels of CA72-4 and CA19-9 are associated with higher risk of death, high pretreatment CEA levels (>50 ng/ml) may predict clinical disease progression after neoadjuvant chemotherapy, and a decrease (>70%) of CA72-4 may predict pathologic response to neoadjuvant chemotherapy.

【 授权许可】

   
2015 Sun and Zhang; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
• [2]Wang CS, Chao TC, Jan YY: Benefits of palliative surgery for far-advanced gastric cancer. Chang Gung Med J 2002, 25:792-802.
• [3]Fink U, Stein HJ, Schuhmacher C, Wilke HJ: Neoadjuvant chemotherapy for gastric cancer: update. World J Surg 1995, 19:509-516.
• [4]Niederhuber JE: Neoadjuvant therapy. Ann Surg 1999, 229:309-312.
• [5]Sakamoto J: Neoadjuvant chemotherapy: a standard treatment for locally advanced gastric cancer in the near future? Gastric Cancer 2003, 6:131-133.
• [6]Mezhir JJ, Tang LH, Coit DG: Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol 2010, 101:305-314.
• [7]Vallbohmer D, Holscher AH, Schneider PM: 18 F-fluorodeoxyglucose- positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 2010, 102:135-140.
• [8]Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ: Gastric cancer. Lancet 2009, 374:477-490.
• [9]Yamao T, Kai S, Kazami A: Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999, 29:550-555.
• [10]Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474.
• [11]Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 2010, 17:3077-3079.
• [12]Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A: (Eds): AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.
• [13]Eisenhauer EA, Therasse P, Bogaerts J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
• [14]Ajani JA, Ota DM, Jessup JM: Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 1991, 68:1501-1506.
• [15]Becker K, Mueller JD, Schulmacher C: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003, 98:1521-1530.
• [16]Ninomiya Y, Yanagisawa A, Kato Y: Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. J Cancer Res Clin Oncol 1999, 125:699-706.
• [17]Moehler M, Schimanski CC, Gockel I: (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis 2004, 22:345-350.
• [18]Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M: Prognostic value of carcinoembryonic antigen, CA 19–9 and CA 72–4 in gastric carcinoma. Tumour Biol 2001, 22:318-322.
• [19]Tocchi A, Costa G, Lepre L: The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol 1998, 124:450-455.
• [20]Ychou M, Duffour J, Kramar A: Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 2000, 16:105-110.
• [21]Ucar E, Semerci E, Ustun H: Prognostic value of preoperative CEA, CA 19–9, CA 72–4, and AFP levels in gastric cancer. Adv Ther 2008, 25:1075-1084.
• [22]Marrelli D, Roviello F, De Stefano A: Prognostic significance of CEA, CA 19–9 and CA 72–4 preoperative serum levels in gastric carcinoma. Oncology 1999, 57:55-62.
• [23]Marrelli D, Pinto E, De Stefano A: Clinical utility of CEA, CA 19–9, and CA 72–4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001, 181:16-19.
• [24]Byrne DJ, Browning MC, Cuschieri A: CA72-4: a new tumour marker for gastric cancer. Br J Surg 1990, 77:1010-1013.
• [25]Spila A, Roselli M, Cosimelli M: Clinical utility of CA 72–4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Anticancer Res 1996, 16:2241-2247.
• [26]Carpelan-Holmstrom M, Louhimo J, Stenman UH: CEA, CA 19–9 and CA 72–4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002, 22:2311-2316.
• [27]Hamazoe R, Maeta M, Matsui T: Ca72-4 compared with carcinoembryonic antigen as a tumor-marker for gastric-cancer. Eur J Cancer 1992, 28A:1351-1354.
• [28]Gonzalez A, Vizoso F, Allende MT: Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma. Int J Biol Markers 1996, 11:165-171.
• [29]Ikeguchi M, Katano K, Saitou H: Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepato-Gastroenterology 1997, 44:866-871.
• [30]Iwanicki-Caron I, Di Fiore F, Roque I: Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008, 26:3681-3686.
• [31]Hess V, Glimelius B, Grawe P: CA 19–9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008, 9:132-138.
• [32]Katz MH, Varadhachary GR, Fleming JB: Serum CA 19–9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010, 17:1794-1801.
• [33]Precht LM, Lowe KA, Atwood M, Beatty JD: Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 2010, 16:362-368.
• [34]Kang S, Kim TJ, Seo SS: Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol 2010, 120:18-22.
• [35]Wanebo JH, Stearns M, Schwartz MK: Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer. Ann Surg 1978, 188:481-493.
• [36]Attiyeh FF, Stearns MW Jr: Second-look laparotomy based on CEA elevations in colorectal cancer. Cancer 1981, 47:2119-2125.